|Bid||0.00 x 900|
|Ask||0.00 x 900|
|Day's range||296.77 - 302.93|
|52-week range||223.25 - 468.55|
|Beta (5Y monthly)||0.39|
|PE ratio (TTM)||15.54|
|Earnings date||19 Oct 2021 - 25 Oct 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||417.70|
In the latest trading session, Biogen Inc. (BIIB) closed at $295.95, marking a -1.98% move from the previous day.
Biogen's (BIIB) new Alzheimer's drug, Aduhelm, can bring in huge revenues, if successfully commercialized.
Shares of Biogen (NASDAQ: BIIB) were sinking 10% this week as of the market close on Thursday. The slide came after the company's CEO stated on Thursday that the launch of Alzheimer's disease drug Aduhelm has been slower than expected. Biogen CEO Michel Vounatsos spoke at the Morgan Stanley 19th Annual Global Healthcare Conference on Thursday.